Volver

Natera Inc

Ticker: NTRA ISIN: US6323071042
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap High beta Trading above 200-day average Near 52-week high
Capitalización
20,91 MM $
Forward P/E
0,00
Profit margin
-14,01%
Revenue growth QoQ
63,90%
Beta
1,65
332,03 $ 2,21%
Precio a fecha de 2026-08-21 · NASDAQ

Rendimiento por período

Rendimientos acumulados
1 Month +28,68%
6 Months +58,60%
1 Year +104,36%
5 Years +23,60% p.a.+188,30%
10 Years +42,22% p.a.+3 277,72%
Since inception +27,22% p.a.+1 360,11%
Rendimientos por año
YTD +44,93%
2025 +44,72%
2024 +152,71%
2023 +55,94%
2022 -56,99%
2021 -6,16%

Key stats

Market cap
20,91 MM
Beta
1,65
52-week range
75.19 - 183.00
50-day MA
168,08
200-day MA
132,74
Section 1

Business overview

Company profile data from fundamentals.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Sector Healthcare
Industry Diagnostics & Research
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -25,82%
ROA -9,96%
Profit margin -14,01%
Operating margin -8,94%
PEG ratio 0,00
Revenue/share TTM 12,59
Revenue TTM 1,53 MM
EBITDA -214,40 M
Gross profit TTM 883,38 M
Beta 1,65

Valuation

Trailing P/E 0,00
Forward P/E 0,00
P/B 24,36
P/S 13,65
EV/EBITDA -26,80
EV/Revenue 13,68
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -1,55
Quarterly earnings growth 0,00%
Revenue TTM 1,53 MM
Reported quarters 40
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 171,93 $
Analyst rating 4.5556

Ownership & short interest

Shares outstanding 132,02 M
Shares float 127,38 M
Institutional ownership 95,51%
Insider ownership 4,32%
Short ratio 3,23
Short % of float 3,54%

Details

Instrument metadata and source update timestamps.

Symbol NTRA
Name Natera Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US6323071042
Country USA
Code + exchange NTRA.NASDAQ
Fundamentals updated 2025-02-26

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.